- Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use(2019)
Auteurs: Quentin Lecocq, Katty Zeven, Y De Vlaeminck, Sandrina Martens, Sam Massa, C Goyvaerts, Geert Raes, Marleen Keyaerts, Karine Breckpot, Nick Devoogdt
- Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages(2019)
Auteurs: Yannick De Vlaeminck, Quentin Lecocq, Philippe Giron, Xenia Geeraerts, Steve Schoonooghe, Kiavash Movahedi, Sam Massa, Evangelia Bolli, Cleo Goyvaerts, Jo A Van Ginderachter, et al.
Pagina's: 107-120
- The journey of in vivo virus engineered dendritic cells from bench to bedside(2018)
Auteurs: C Goyvaerts, Karine Breckpot
Pagina's: 2052
- Turn Back the TIMe(2018)
Auteurs: Robin Maximilian Awad, Y De Vlaeminck, Johannes Maebe, C Goyvaerts, Karine Breckpot
Pagina's: 1977
- Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2(2016)
Auteurs: Zhuo Ren, Joeri L Aerts, Hugo Vandenplas, Jiance A Wang, Olena Gorbenko, Jack P Chen, Philippe Giron, Carlo Heirman, Cleo Goyvaerts, Eldad Zacksenhaus, et al.
- Cancer-Associated Myeloid Regulatory Cells(2016)
Auteurs: Yannick De Vlaeminck, Anna Arely González Rascón, Cleo Goyvaerts, Karine Breckpot
- Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells(2016)
Auteurs: Sandra Van Lint, Dries Renmans, Katrijn Broos, Lode Goethals, Sarah Maenhout, Daphné Benteyn, Cleo Goyvaerts, Stephanie Du Four, Kevin Van Der Jeught, Lukasz Bialkowski, et al.
Pagina's: 146-156
- The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome(2015)
Auteurs: C Goyvaerts, Katrijn Broos, David Escors, Carlo Heirman, Geert Raes, Patrick De Baetselier, Kris Thielemans, Karine Breckpot
Pagina's: 3351-3361
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines(2015)
Auteurs: C Goyvaerts, Karine Breckpot
- Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy(2014)
Auteurs: Therese Liechtenstein, Noemi Perez-Janices, Idoia Blanco-Luquin, Cleo Goyvaerts, Julia Katharina Schwarze, Inès Dufait, Alessio Lanna, Mark De Ridder, David Guerrero-Setas, Karine Breckpot, et al.